# Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA

> **NCT04470804** · PHASE4 · COMPLETED · sponsor: **Bing Han** · enrollment: 56 (actual)

## Conditions studied

- Pure Red Cell Aplasia, Acquired

## Interventions

- **DRUG:** Sirolimus
- **DRUG:** Cyclosporine A

## Key facts

- **NCT ID:** NCT04470804
- **Lead sponsor:** Bing Han
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-07-31
- **Target enrollment:** 56 (ACTUAL)
- **Last updated:** 2023-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04470804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04470804, "Sirolimus Treatment for Newly Diagnosed Primary Acquired PRCA". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04470804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*